Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
PLoS MedicinePublished 2 September 2009Open access
Joseph S. Ross, Gregory K. Mulvey, Elizabeth M. Hines, Steven E. Nissen, Harlan M. Krumholz
Citations395
SJR quartileQ1
SJR score4.28
SNIP3.21
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Joseph Ross and colleagues examine publication rates of clinical trials and find low rates of publication even following registration in Clinicaltrials.gov.
Abstract
Reporting of optional data elements varied and publication rates among completed trials registered within ClinicalTrials.gov were low. Without greater attention to reporting of all data elements, the potential for ClinicalTrials.gov to address selective publication of clinical trials will be limited. Please see later in the article for the Editors' Summary.
Keywords
Decision SciencesMedicineEconomics, Econometrics and Finance
New England Journal of MedicineEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
4,666 Citations2007Steven E. Nissen, Kathy Wolski
Patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes mellitus as well as the availability of outcome data for myocardial infarction and death from cardiovascular causes.
JAMAGastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
3,151 Citations2000Fred E. Silverstein, Gerald A. Faich +14 more
In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
The LancetPublication bias in clinical research
3,095 Citations1991Philippa Easterbrook, Radha Gopalan +2 more
The presence of publication bias in a cohort of clinical research studies is confirmed and it is suggested that conclusions based only on a review of published data should be interpreted cautiously, especially for observational studies.
New England Journal of MedicineSelective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy
2,426 Citations2008Erick H. Turner, Annette M. Matthews +3 more
A systematic literature search found that among 74 FDA-registered studies, 31%, accounting for 3449 study participants, were not published, and the increase in effect size ranged from 11 to 69% for individual drugs and was 32% overall.
BMJPharmaceutical industry sponsorship and research outcome and quality: systematic review
2,163 Citations2003Joel Lexchin, Lisa A Bero +2 more
Investigating whether funding of drug studies by the pharmaceutical industry is associated with outcomes that are favourable to the funder and whether the methods of trials funded by pharmaceutical companies differ from the methods in trials with other sources of support found systematic bias favours products which are made by the company funding the research.
JAMAEmpirical Evidence for Selective Reporting of Outcomes in Randomized Trials
1,806 Citations2004An‐Wen Chan, Asbjørn Hróbjartsson +3 more
The reporting of trial outcomes is not only frequently incomplete but also biased and inconsistent with protocols and Published articles, as well as reviews that incorporate them, may therefore be unreliable and overestimate the benefits of an intervention.
JAMARisk of Cardiovascular Events Associated With Selective COX-2 Inhibitors
1,742 Citations2001Debabrata Mukherjee
The results from VIGOR showed that the relative risk of developing a confirmed adjudicated thrombotic cardiovascular event with rofecoxib treatment compared with naproxen was higher than that in the placebo group of a recent meta-analysis of 23 407 patients in primary prevention trials.
PLoS ONESystematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
1,506 Citations2008Kerry Dwan, Douglas G. Altman +12 more
There is strong evidence of an association between significant results and publication; studies that report positive or significant results are more likely to be published and outcomes that are statistically significant have higher odds of being fully reported.
New England Journal of MedicineClinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
1,211 Citations2004Catherine De Angelis, Jeffrey M. Drazen +11 more
JAMAFactors Influencing Publication of Research Results
853 Citations1992Kay Dickersin
There was evidence of publication bias in that for both institutional review boards there was an association between results reported to be significant and publication and contrary to popular opinion, publication bias originates primarily with investigators, not journal editors.
BMJPublication bias: evidence of delayed publication in a cohort study of clinical research projects
829 Citations1997Jerome M Stern, R. J. Simes
JAMAVenous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
720 Citations2008Charles L. Bennett
Erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of venous thromboembolism (VTE) and mortality, and these findings raise concern about the safety of ESA administration to Patients with cancer.
JAMAEffect of the Statistical Significance of Results on the Time to Completion and Publication of Randomized Efficacy Trials
629 Citations1998John P. A. Ioannidis
There is a time lag in the publication of negative findings that occurs mostly after the completion of the trial follow-up among randomized efficacy trials.
JAMAWithholding Research Results in Academic Life Science
583 Citations1997David Blumenthal
Withholding of research results is not a widespread phenomenon among life-science researchers, however, withholding is more common among the most productive and entrepreneurial faculty.
Canadian Medical Association JournalOutcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research
446 Citations2004A.-W. Chan
Whether outcome reporting bias would be present in a cohort of government-funded trials subjected to rigorous peer review and whether primary outcomes specified in trial protocols were compared with those reported in publications is compared.
Annals of the New York Academy of SciencesPublication Bias: The Problem That Won't Go Away
429 Citations1993Kay Dickersin, Yuan‐I Min
Meta-analyses performed using data from four prospective investigations in which a total of 997 initiated studies were followed to learn of study results, publication status, and reasons for nonpublication indicate that there is a positive association between "significant" study results and publication.
BMJAre selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
397 Citations2002Peter Jüni, Anne WS Rutjes +1 more
The celecoxib long term arthritis safety study, better known as CLASS, concluded that a COX 2 inhibitor was associated with a lower incidence of complications than traditional non-steroidal anti-inflammatory drugs, and criticisms that contradicted this conclusion were criticised.
PLoS MedicineReporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation
322 Citations2008Kristin L. Rising, Peter Bacchetti +1 more
The publication rate of efficacy trials submitted to the Food and Drug Administration in approved New Drug Applications (NDAs) is determined and the trial characteristics as reported by the FDA with those reported in publications are compared.
JAMAFactors Associated With Failure to Publish Large Randomized Trials Presented at an Oncology Meeting
313 Citations2003Monika K. Krzyzanowska
A substantial number of large phase 3 trials presented at an international oncology meeting remain unpublished 5 years after presentation, suggesting bias against publishing nonsignificant results is a problem even for large randomized trials.
PubMedNIH clinical trials and publication bias.
298 Citations1993Kay Dickersin, Yuan‐I Min
Even when the overall publication rate is high, such as for trials funded by the NIH, publication bias remains a significant problem and more reliable systems for maintaining information about initiated studies are needed.
New England Journal of MedicineTrial Registration at ClinicalTrials.gov between May and October 2005
295 Citations2005Deborah A. Zarin, Tony Tse +1 more
Overall, the data contained in records were more complete in October than they were in May, but there still is room for substantial improvement.
JAMAIssues in the Registration of Clinical Trials
218 Citations2007Deborah A. Zarin, Nicholas C. Ide +4 more
Several issues confound the implementation of such a database, including the lack of an accepted format or process for providing summaries of trial results to the public and concerns about disseminating data in the absence of independent scientific review.
PLoS MedicinePublication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis
217 Citations2008Kirby Lee, Peter Bacchetti +1 more
The proportion of trials submitted to the FDA in support of newly approved drugs that are published in biomedical journals that a typical clinician, consumer, or policy maker living in the US would reasonably search is determined.
BMJFate of biomedical research protocols and publication bias in France: retrospective cohort study
154 Citations2005Évelyne Decullier, Véronique Lhéritier +1 more
Too many research studies are not completed, and among those completed too many are not published, at a national level; capitalising on research ethics committees to register and follow all authorised research on human participants on a systematic and prospective basis.
JAMAPublication Bias and Research on Passive Smoking
127 Citations1998Anastasia L. Misakian, Lisa Bero
Swiss Medical WeeklyPublication and non-publication of clinical trials: longitudinal study of applications submitted to a research ethics committee
112 Citations2008Erik von Elm, Alexandra Röllin +1 more
British Journal of Clinical PharmacologyBias in reporting clinical trials
70 Citations1998A. Bardy
Substantial evidence of selective reporting was detected, since trials with positive outcome resulted more often in submission of final report to regulatory authority than those with inconclusive or negative outcomes.
Journal of the American Geriatrics SocietyEfficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled Trial
33 Citations2004Alan Kivitz, Maria Greenwald +12 more
The use of starting doses of rofecoxib and nabumetone in patients with osteoarthritis of the knee are evaluated for the first time.
JCR Journal of Clinical RheumatologyTreatment of Patients With Osteoarthritis With Rofecoxib Compared With Nabumetone
19 Citations2006Arthur L. Weaver, Ronald P. Messner +6 more
Rofecoxib at a dosage of 12.5 mg demonstrated significantly better efficacy in PGART than 1000 mg nabumetone in these patients known to be NSAID responders, at their recommended starting doses for OA.